Skip to main content
Top
Published in: Angiogenesis 3/2009

01-09-2009 | Original paper

Wnt2 acts as an angiogenic growth factor for non-sinusoidal endothelial cells and inhibits expression of stanniocalcin-1

Authors: Diana Klein, Alexandra Demory, Francis Peyre, Jens Kroll, Cyrill Géraud, Nils Ohnesorge, Kai Schledzewski, Bernd Arnold, Sergij Goerdt

Published in: Angiogenesis | Issue 3/2009

Login to get access

Abstract

Recently, we have shown that Wnt2 is an autocrine growth and differentiation factor for hepatic sinusoidal endothelial cells. As Wnt signaling has become increasingly important in vascular development and cancer, we analyzed Wnt signaling in non-sinusoidal endothelial cells of different vascular origin (HUVEC, HUAEC, HMVEC-LLy). Upon screening the multiple components of the Wnt pathway, we demonstrated lack of Wnt2 expression, but presence of Frizzled-4, one of its receptors, in cultured non-sinusoidal endothelial cells. Treatment of these cells by exogenous Wnt2 induced endothelial proliferation and sprouting angiogenesis in vitro. Upon analysis of Wnt2 tissue expression as a basis for paracrine Wnt2 effects on non-sinusoidal endothelial cells in vivo, Wnt2 was found to be expressed in densely vascularized murine malignant tumors and in wound healing tissues in close proximity to CD31+ endothelial cells. By gene profiling, stanniocalcin-1 (STC1), a known regulator of angiogenesis, was identified as a target gene of Wnt2 signaling in HUVEC down-regulated by Wnt2 treatment. Tumor-conditioned media counter-acted Wnt2 and up-regulated STC1 expression in HUVEC. In conclusion, we provide evidence that Wnt2 acts as an angiogenic factor for non-sinusoidal endothelium in vitro and in vivo whose target genes undergo complex regulation by the tissue microenvironment.
Literature
1.
go back to reference Polakis P (2000) Wnt signaling and cancer. Genes Dev 14:1837–1851PubMed Polakis P (2000) Wnt signaling and cancer. Genes Dev 14:1837–1851PubMed
7.
go back to reference Ishikawa T, Tamai Y, Zorn AM et al (2001) Mouse Wnt receptor gene Fzd5 is essential for yolk sac and placental angiogenesis. Development 128:25–33PubMed Ishikawa T, Tamai Y, Zorn AM et al (2001) Mouse Wnt receptor gene Fzd5 is essential for yolk sac and placental angiogenesis. Development 128:25–33PubMed
10.
13.
go back to reference Wu WB, Peng HC, Huang TF (2003) Disintegrin causes proteolysis of beta-catenin and apoptosis of endothelial cells. Involvement of cell–cell and cell–ECM interactions in regulating cell viability. Exp Cell Res 286:115–127. doi:10.1016/S0014-4827(03)00105-8 PubMedCrossRef Wu WB, Peng HC, Huang TF (2003) Disintegrin causes proteolysis of beta-catenin and apoptosis of endothelial cells. Involvement of cell–cell and cell–ECM interactions in regulating cell viability. Exp Cell Res 286:115–127. doi:10.​1016/​S0014-4827(03)00105-8 PubMedCrossRef
14.
go back to reference Klein D, Demory A, Peyre F et al (2008) Wnt2 acts as a cell type-specific, autocrine growth factor in rat hepatic sinusoidal endothelial cells cross-stimulating the VEGF pathway. Hepatology 47:1018–1031. doi:10.1002/hep.22084 PubMedCrossRef Klein D, Demory A, Peyre F et al (2008) Wnt2 acts as a cell type-specific, autocrine growth factor in rat hepatic sinusoidal endothelial cells cross-stimulating the VEGF pathway. Hepatology 47:1018–1031. doi:10.​1002/​hep.​22084 PubMedCrossRef
16.
go back to reference Monkley SJ, Delaney SJ, Pennisi DJ, Christiansen JH, Wainwright BJ (1996) Targeted disruption of the Wnt2 gene results in placentation defects. Development 122:3343–3353PubMed Monkley SJ, Delaney SJ, Pennisi DJ, Christiansen JH, Wainwright BJ (1996) Targeted disruption of the Wnt2 gene results in placentation defects. Development 122:3343–3353PubMed
17.
go back to reference Giovarelli M, Musiani P, Modesti A et al (1995) Local release of IL-10 by transfected mouse mammary adenocarcinoma cells does not suppress but enhances antitumor reaction and elicits a strong cytotoxic lymphocyte and antibody-dependent immune memory. J Immunol 155:3112–3123PubMed Giovarelli M, Musiani P, Modesti A et al (1995) Local release of IL-10 by transfected mouse mammary adenocarcinoma cells does not suppress but enhances antitumor reaction and elicits a strong cytotoxic lymphocyte and antibody-dependent immune memory. J Immunol 155:3112–3123PubMed
18.
go back to reference Falkowski M, Schledzewski K, Hansen B, Goerdt S (2003) Expression of stabilin-2, a novel fasciclin-like hyaluronan receptor protein, in murine sinusoidal endothelia, avascular tissues, and at solid/liquid interfaces. Histochem Cell Biol 120:361–369. doi:10.1007/s00418-003-0585-5 PubMedCrossRef Falkowski M, Schledzewski K, Hansen B, Goerdt S (2003) Expression of stabilin-2, a novel fasciclin-like hyaluronan receptor protein, in murine sinusoidal endothelia, avascular tissues, and at solid/liquid interfaces. Histochem Cell Biol 120:361–369. doi:10.​1007/​s00418-003-0585-5 PubMedCrossRef
22.
go back to reference Goodwin AM, Sullivan KM, D’Amore PA (2006) Cultured endothelial cells display endogenous activation of the canonical Wnt signaling pathway and express multiple ligands, receptors, and secreted modulators of Wnt signaling. Dev Dyn 235:3110–3120. doi:10.1002/dvdy.20939 PubMedCrossRef Goodwin AM, Sullivan KM, D’Amore PA (2006) Cultured endothelial cells display endogenous activation of the canonical Wnt signaling pathway and express multiple ligands, receptors, and secreted modulators of Wnt signaling. Dev Dyn 235:3110–3120. doi:10.​1002/​dvdy.​20939 PubMedCrossRef
26.
go back to reference Watanabe O, Imamura H, Shimizu T et al (2004) Expression of twist and Wnt in human breast cancer. Anticancer Res 24:3851–3856PubMed Watanabe O, Imamura H, Shimizu T et al (2004) Expression of twist and Wnt in human breast cancer. Anticancer Res 24:3851–3856PubMed
33.
go back to reference Gerritsen ME, Tomlinson JE, Zlot C et al (2003) Using gene expression profiling to identify the molecular basis of the synergistic actions of hepatocyte growth factor and vascular endothelial growth factor in human endothelial cells. Br J Pharmacol 140:595–610. doi:10.1038/sj.bjp.0705494 PubMedCrossRef Gerritsen ME, Tomlinson JE, Zlot C et al (2003) Using gene expression profiling to identify the molecular basis of the synergistic actions of hepatocyte growth factor and vascular endothelial growth factor in human endothelial cells. Br J Pharmacol 140:595–610. doi:10.​1038/​sj.​bjp.​0705494 PubMedCrossRef
35.
go back to reference David M, Yeramian A, Dunach M et al (2008) Signaling by neurotrophins and hepatocyte growth factor regulates axon morphogenesis by differential β-catenin phosphorylation. J Cell Sci 121:2718–2730. doi:10.1242/jcs.029660 PubMedCrossRef David M, Yeramian A, Dunach M et al (2008) Signaling by neurotrophins and hepatocyte growth factor regulates axon morphogenesis by differential β-catenin phosphorylation. J Cell Sci 121:2718–2730. doi:10.​1242/​jcs.​029660 PubMedCrossRef
36.
go back to reference Wascher RA, Huynh KT, Giuliano AE et al (2003) Stanniocalcin-1: a novel molecular blood and bone marrow marker for human breast cancer. Clin Cancer Res 9:1427–1435PubMed Wascher RA, Huynh KT, Giuliano AE et al (2003) Stanniocalcin-1: a novel molecular blood and bone marrow marker for human breast cancer. Clin Cancer Res 9:1427–1435PubMed
Metadata
Title
Wnt2 acts as an angiogenic growth factor for non-sinusoidal endothelial cells and inhibits expression of stanniocalcin-1
Authors
Diana Klein
Alexandra Demory
Francis Peyre
Jens Kroll
Cyrill Géraud
Nils Ohnesorge
Kai Schledzewski
Bernd Arnold
Sergij Goerdt
Publication date
01-09-2009
Publisher
Springer Netherlands
Published in
Angiogenesis / Issue 3/2009
Print ISSN: 0969-6970
Electronic ISSN: 1573-7209
DOI
https://doi.org/10.1007/s10456-009-9145-5

Other articles of this Issue 3/2009

Angiogenesis 3/2009 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine